Why is "Bretisilocin" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-07-29 01:59:29
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Bretisilocin entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-07-29 and was most recently seen on 2026-07-29.
Wikipedia Overview
Bretisilocin, also known by its developmental code name GM-2505 and as 5-fluoro-N-methyl-N-ethyltryptamine, is a serotonergic psychedelic of the tryptamine family which is under development for the treatment of major depressive disorder. It is an analogue of dimethyltryptamine (DMT) and is the 5-fluorinated derivative of methylethyltryptamine (MET). Bretisilocin's route of administration is intravenous infusion.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Developing Next-Generation Psychedelic Treatments: Insights on Bretisilocin From AJ Cannon, MD - Psychiatric Times
-
New analysis: Psychedelics may be no better than SSRIs in treating depression, Kentucky ibogaine bill and New Mexico psilocybin equity fund - The Microdose | Substack
-
AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin - PR Newswire
-
AbbVie CSO Touts ‘Breakthrough Type Therapy’ Psychedelic as J&J’s Spravato Keeps Growing - BioSpace
-
Could a short-acting psychedelic transform depression treatment? - Drug Discovery News
-
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy - microdose.buzz
-
AbbVie Finalizes Acquisition of Gilgamesh Pharmaceuticals’ Experimental Drug Bretisilocin - The Healthcare Technology Report.
-
AbbVie to Acquire Gilgamesh’s Bretisilocin for Up to $1.2B - Psychedelic Alpha
-
AbbVie tunes in to Gilgamesh's story, inking $1.2B deal for psychedelic program - Fierce Biotech
-
AbbVie completes acquisition of Gilgamesh Pharmaceuticals' Bretisilocin - Indian Pharma Post
-
AbbVie strikes $1.2B deal for Gilgamesh's psychedelic depression therapy - FirstWord Pharma
-
AbbVie agrees to acquire Gilgamesh’s bretisilocin for $1.2bn - Yahoo Finance
-
AbbVie Enters Psychedelic Market With Bretisilocin Acquisition - Pharmaceutical Online
-
AbbVie Expands Psychiatry Drug Pipeline with Acquisition of Gilgamesh Pharmaceuticals’ Bretisilocin for Major Depressive Disorder - Pharmaceutical Executive
-
AbbVie to acquire Gilgamesh’s bretisilocin - The Pharma Letter
-
AbbVie to Acquire Gilgamesh Pharmaceutical’s Psychedelic Drug for $1.2B - CHEManager
-
AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline - PR Newswire
-
AbbVie Embraces Psychedelic Drug with Up-to-$1.2B Deal for Gilgamesh's MDD Candidate - Alex Philippidis, 2025 - Sage Journals
-
Gilgamesh’s Next-Gen Psychedelic GM-2505 Prints Impressive Results in Phase 2a Major Depressive Disorder Study - Psychedelic Alpha
-
Gilgamesh Pharmaceuticals Announces Positive Topline Phase 2a Results for GM-2505 in Major Depressive Disorder (MDD) - PR Newswire
-
Pharmaceutical company AbbVie to buy Gilgamesh depression drug program for up to $1.2 billion; Kentucky committee discusses ibogaine; and Colorado listening session on Natural Medicine Program - The Microdose | Substack
-
AbbVie to buy Gilgamesh’s psychedelic drug for up to $1.2 billion - STAT
-
AbbVie to Acquire Investigational Therapy for $2.1B - Powder & Bulk Solids
-
AbbVie to Buy Gilgamesh Depression Drug for Up to $1.2 Billion - Bloomberg.com
-
AbbVie targets psychedelic-based depression drug market with $1.2 billion deal - Reuters
-
AbbVie dives back into the neuro pool with a $1.2B psychedelics play - Pharma Voice
-
AbbVie Acquires Gilgamesh’s Psychedelic MDD Program For Up To $1.2B - HIT Consultant
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.